Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical effects of everolimus in the subjects with tuberous sclerosis

Trial Profile

Clinical effects of everolimus in the subjects with tuberous sclerosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary)
  • Indications Tuberous sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Sep 2022 Planned number of patients changed from 45 to 20.
    • 27 Sep 2021 Planned End Date changed to 10 Apr 2026.
    • 27 Sep 2021 Timepoint of primary endpoint has been changed from September, 2023 to September, 2026
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top